NCI clinical trials
Executive Summary
GAO investigation initiated by Rep. Waxman (D-Calif.) is "primarily identifying why a number of patients have died prematurely," National Cancer Institutes Vincent DeVita, MD, noted at a recent meeting of the National Cancer Advisory Board. GAO also requested information about interleukin-2/LAK therapy, specifically whether clinical results supported expanded use of the treatment.